A Phase Ib Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Patients With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma
This Phase Ib, open-label, multicenter study evaluates the safety, efficacy, and
pharmacokinetics of venetoclax in combination with Pola + R-CHP in previously untreated
participants with BCL-2 IHC-positive DLBCL. Approximately 50 participants will be enrolled in
this study in five consecutive cohorts each consisting of approximately 10 participants.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.